

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: AKS3/17 - Basic Clinical Chemistry - Serum

Dead line: 28.07.2017

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | | | |
|----------------------------------|----------|---------------|------|--------|------------------|----------------------|--------------|-----------------|------------------|------|------|------------------|------------------|---------------------------|-------|-----------------|------------------|------|------|------------------|------------------|------------------|------|-----|------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | | | |
| (4) Calcium | | | | | 109 | | | | | | | 0 | | | | | | | | | 109 | 109 | 100% | | |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 2,60 | 0,07 | 2,8 | 109 | | | | | | | 0 | | CRV | 2,605 | 0,039 | 10% | 2,34 | 2,87 | 109 | 109 | 100% | | | |
| (4) Complex Ca-NM-BAPTA | | 2,63 | 0,05 | 1,9 | 25 | 0 | | | | | | | | | | | | | | | 25 | | | | |
| (6) ISE | | 2,64 | 0,05 | 2,0 | 5 | 0 | | | | | | | | | | | | | | | 5 | | | | |
| Sample B | | 3,04 | 0,07 | 2,4 | 109 | | | | | | | 0 | | CRV | 3,02 | 0,045 | 10% | 2,71 | 3,33 | 109 | 109 | 100% | | | |
| (2) Phot. with o-cresolftalexon | | 3,02 | 0,09 | 3,3 | 21 | 0 | | | | | | | | | | | | | | | 21 | | | | |
| (3) Photom. with arsenazo III | | 3,03 | 0,07 | 2,3 | 58 | 0 | | | | | | | | | | | | | | | 58 | | | | |
| (4) Complex Ca-NM-BAPTA | | 3,07 | 0,06 | 2,0 | 25 | 0 | | | | | | | | | | | | | | | 25 | | | | |
| (6) ISE | | 3,05 | 0,03 | 1,2 | 5 | 0 | | | | | | | | | | | | | | | 5 | | | | |
| (5) Inorganic phosphate | | | | | 104 | | | | | | | 104 | 104 | 100% | | | | | | | | | 0 | | |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,70 | 0,05 | 3,2 | 104 | CRV | 1,7 | 0,013 | 10% | 1,53 | 1,87 | 104 | 104 | 100% | | | | | | | | | 0 | | |
| (1) UV-molybdate method | | 1,71 | 0,05 | 3,1 | 102 | 0 | | | | | | 102 | | | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | 2 | | | | | | | | | | | | | |
| Sample B | | 1,97 | 0,05 | 2,7 | 104 | ^{2x 2} CVP | 1,97 | 0,013 | 10% | 1,77 | 2,17 | 104 | 104 | 100% | | | | | | | | | 0 | | |
| (1) UV-molybdate method | | 1,97 | 0,05 | 2,8 | 102 | 0 | | | | | | 102 | | | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | 2 | | | | | | | | | | | | | |
| (6) Iron | | | | | 99 | | | | | | | 99 | 99 | 100% | | | | | | | | | 0 | | |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 23,1 | 0,88 | 3,8 | 99 | CVP | 23,1 | 0,22 | 15% | 19,6 | 26,6 | 99 | 99 | 100% | | | | | | | | | 0 | | |
| (2) Method with ferrozine/ferene | | 23,2 | 0,90 | 3,9 | 76 | 0 | | | | | | 76 | | | | | | | | | | | | | |
| (4) Method with TPTZ | | 22,7 | 0,62 | 2,7 | 21 | 0 | | | | | | 21 | | | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | 2 | | | | | | | | | | | | | |
| Sample B | | 29,5 | 0,93 | 3,2 | 99 | ^{2x 99} CVP | 29,5 | 0,23 | 15% | 25 | 34 | 99 | 99 | 100% | | | | | | | | | 0 | | |
| (2) Method with ferrozine/ferene | | 29,7 | 0,90 | 3,0 | 76 | 0 | | | | | | 76 | | | | | | | | | | | | | |
| (4) Method with TPTZ | | 28,9 | 0,80 | 2,8 | 21 | 0 | | | | | | 21 | | | | | | | | | | | | | |
| Other | | | | | 2 | 0 | | | | | | 2 | | | | | | | | | | | | | |
| (7) Magnesium | | | | | 103 | | | | | | | 0 | | | | | | | | | | | 103 | 102 | 99% |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,49 | 0,05 | 3,8 | 103 | | | | | | | 0 | | CRV | 1,479 | 0,022 | 15% | 1,25 | 1,71 | 103 | 102 | 99% | | | |
| (2) Photometry | | 1,49 | 0,05 | 4,0 | 88 | 0 | | | | | | | | | | | | | | | | 88 | | | |
| (4) UV enzyme method | | 1,49 | 0,04 | 3,1 | 15 | 0 | | | | | | | | | | | | | | | | 15 | | | |
| Sample B | | 1,99 | 0,07 | 3,9 | 103 | | | | | | | 0 | | CRV | 1,97 | 0,030 | 15% | 1,67 | 2,27 | 103 | 103 | 100% | | | |
| (2) Photometry | | 1,98 | 0,07 | 4,0 | 88 | 0 | | | | | | | | | | | | | | | | 88 | | | |
| (4) UV enzyme method | | 2,02 | 0,06 | 3,2 | 15 | 0 | | | | | | | | | | | | | | | | 15 | | | |
| (8) Lithium | | | | | 19 | | | | | | | 0 | | | | | | | | | | | 19 | 19 | 100% |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,21 | 0,05 | 4,8 | 19 | | | | | | | 0 | | CRV | 1,238 | 0,020 | 12% | 1,08 | 1,39 | 19 | 19 | 100% | | | |
| (1) Flame emission phot. | | 1,19 | 0,05 | 5,0 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | | |
| (4) Photometry | | 1,22 | 0,06 | 5,6 | 8 | 0 | | | | | | | | | | | | | | | | 8 | | | |
| Other | | | | | 5 | 0 | | | | | | | | | | | | | | | | 5 | | | |
| Sample B | | 1,82 | 0,08 | 4,4 | 19 | | | | | | | 0 | | ^{1x 2, 4x 3} CRV | 1,853 | 0,028 | 12% | 1,63 | 2,08 | 19 | 19 | 100% | | | |

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: AKS3/17 - Basic Clinical Chemistry - Serum

Dead line: 28.07.2017

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | |
|---|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|------|------|------------------|------------------|------------------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} |
| (13) Bilirubin total | | | | | 117 | | | | | | | | | |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | |
| Sample A | | 57,4 | 3,7 | 6,5 | 117 | | | | | | | | | |
| (1) Jendrassik-Gróf | | 57,4 | 3,3 | 5,7 | 21 | 0 | | | CRV | 57,2 | 1,3 | 21% | 45,1 | 69,3 |
| (2) DCA, DPD | | 57,0 | 3,8 | 6,6 | 82 | 0 | | | | | | | | |
| (4) Oxidation-reduction methods | | 60,3 | 1,5 | 2,4 | 13 | 0 | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | | | |
| | | | | | | | | | 1x0 | | | | | |
| Sample B | | 74,9 | 4,7 | 6,3 | 117 | | | | CRV | 76 | 1,7 | 21% | 60 | 92 |
| (1) Jendrassik-Gróf | | 75,7 | 4,4 | 5,8 | 21 | 0 | | | | | | | | |
| (2) DCA, DPD | | 74,0 | 4,4 | 5,9 | 82 | 0 | | | | | | | | |
| (4) Oxidation-reduction methods | | 79,7 | 2,1 | 2,6 | 13 | 0 | | | | | | | | |
| Other | | | | | 1 | 0 | | | | | | | | |
| | | | | | | | | | 1x0 | | | | | |
| (15) Cholesterol | | | | | 110 | | | | | | | | | |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | |
| Sample A | | 3,52 | 0,13 | 3,8 | 110 | | | | | | | | | |
| (1) Enzyme CHOD-PAP | | 3,53 | 0,12 | 3,3 | 101 | 0 | | | | | | | | |
| (1) Enzyme CHOD-PAP; (149) Siemens (Dade) | | 3,04 | 0,17 | 5,6 | 8 | 0 | CVPG | 3,06 | 0,12 | 6,9% | 2,84 | 3,28 | | |
| Other | | | | | 1 | 0 | | | | | | | | |
| | | | | | | | | | 1x0/149 | | | | | |
| Sample B | | 4,64 | 0,18 | 3,9 | 110 | | | | | | | | | |
| (1) Enzyme CHOD-PAP | | 4,67 | 0,16 | 3,4 | 101 | 0 | | | | | | | | |
| (1) Enzyme CHOD-PAP; (149) Siemens (Dade) | | 4,08 | 0,21 | 5,1 | 8 | 0 | CVPG | 4,08 | 0,15 | 6,9% | 3,79 | 4,37 | | |
| Other | | | | | 1 | 0 | | | | | | | | |
| | | | | | | | | | 1x0/149 | | | | | |
| (16) Glucose | | | | | 118 | | | | | | | | | |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | |
| Sample A | | 8,90 | 0,22 | 2,4 | 118 | | | | | | | | | |
| (1) GOD photometry | | 8,88 | 0,20 | 2,2 | 22 | 0 | | | | | | | | |
| (3) Method with hexokinase | | 8,91 | 0,23 | 2,6 | 92 | 0 | | | | | | | | |
| Other | | | | | 4 | 0 | | | | | | | | |
| | | | | | | | | | 4x2 | | | | | |
| Sample B | | 11,9 | 0,28 | 2,3 | 118 | | | | | | | | | |
| (1) GOD photometry | | 12,0 | 0,29 | 2,4 | 22 | 0 | | | | | | | | |
| (3) Method with hexokinase | | 11,9 | 0,29 | 2,4 | 92 | 0 | | | | | | | | |
| Other | | | | | 4 | 0 | | | | | | | | |
| | | | | | | | | | 4x2 | | | | | |
| (17) Uric acid | | | | | 115 | | | | | | | | | |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | |
| Sample A | | 249 | 9,9 | 4,0 | 115 | | | | | | | | | |
| (2) Enzyme-photomet. m. | | 249 | 9,9 | 4,0 | 115 | 0 | | | | | | | | |
| Sample B | | 311 | 11 | 3,5 | 115 | | | | | | | | | |
| (2) Enzyme-photomet. m. | | 311 | 11 | 3,5 | 115 | 0 | | | | | | | | |

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: AKS3/17 - Basic Clinical Chemistry - Serum

Dead line: 28.07.2017

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|---------------------------------------|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|------|------|------------------|--------------------|------------------|-------|-------|-------|------|------|------|-----|-----|--|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | | | | | | | | | |
| (18) Urea | | | | | 117 | | | | | | | 0 | | | | 117 | 115 | 98% | | | | | |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 25,4 | 0,85 | 3,3 | 117 | | | | | | | 0 | CRV | 26,26 | 0,26 | 15% | 22,3 | 30,2 | 117 | 115 | 98% | | |
| (1) UV enzymatic m.(GMD) | | 25,4 | 0,84 | 3,3 | 112 | 0 | | | | | | | | | | | | | 112 | | | | |
| Other | | | | | 5 | 0 | | | | | | | | | | | | | | 5 | | | |
| Sample B | | 9,96 | 0,35 | 3,5 | 117 | | | | | | | 0 | 4x 5, 1x 99 CRV | 10,09 | 0,100 | 15% | 8,57 | 11,7 | 117 | 116 | 99% | | |
| (1) UV enzymatic m.(GMD) | | 9,96 | 0,34 | 3,4 | 112 | 0 | | | | | | | | | | | | | | 112 | | | |
| Other | | | | | 5 | 0 | | | | | | | | | | | | | | 5 | | | |
| | | | | | | | | | | | | | 4x 5, 1x 99 | | | | | | | | | | |
| (19) Creatinine | | | | | 120 | | | | | | | 0 | | | | | | | | 120 | 115 | 96% | |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 510 | 17 | 3,3 | 120 | | | | | | | 0 | CRV | 511,5 | 5,1 | 15% | 434 | 589 | 120 | 119 | 99% | | |
| (2) Jaffé without depro. (with corr.) | | 505 | 18 | 3,7 | 54 | 0 | | | | | | | | | | | | | | 54 | | | |
| (3) Enzyme | | 514 | 15 | 2,8 | 65 | 0 | | | | | | | | | | | | | | 65 | | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | 1 | | | |
| Sample B | | 152 | 8,1 | 5,4 | 120 | | | | | | | 0 | 1x 1 CRV | 151,1 | 1,5 | 15% | 128 | 174 | 120 | 115 | 96% | | |
| (2) Jaffé without depro. (with corr.) | | 158 | 12 | 7,8 | 54 | 0 | | | | | | | | | | | | | | 54 | | | |
| (3) Enzyme | | 149 | 4,8 | 3,2 | 65 | 0 | | | | | | | | | | | | | | 65 | | | |
| Other | | | | | 1 | 0 | | | | | | | | | | | | | | 1 | | | |
| | | | | | | | | | | | | | 1x 1 | | | | | | | | | | |
| (20) Triglycerides | | | | | 110 | | | | | | | 0 | | | | | | | | 110 | 109 | 99% | |
| Samples and groups | [mmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,10 | 0,05 | 5,4 | 110 | | | | | | | 0 | CRV | 1,065 | 0,011 | 15% | 0,905 | 1,23 | 110 | 109 | 99% | | |
| (1) GPO-PAP | | 1,09 | 0,05 | 5,4 | 105 | 0 | | | | | | | | | | | | | | 105 | | | |
| (2) Enzymatic UV method | | 1,13 | 0,06 | 5,9 | 5 | 0 | | | | | | | | | | | | | | 5 | | | |
| Sample B | | 1,96 | 0,08 | 4,3 | 110 | | | | | | | 0 | CRV | 2,03 | 0,020 | 15% | 1,72 | 2,34 | 110 | 109 | 99% | | |
| (1) GPO-PAP | | 1,95 | 0,08 | 4,2 | 105 | 0 | | | | | | | | | | | | | | 105 | | | |
| (2) Enzymatic UV method | | 1,94 | 0,08 | 4,6 | 5 | 0 | | | | | | | | | | | | | | 5 | | | |
| (21) ALP | | | | | 116 | | | | | | | 36 | 35 | 97% | | | | | | 80 | 77 | 96% | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 3,34 | 0,42 | 13 | 116 | | | | | | | 36 | 35 | 97% | | | | | | 80 | 79 | 99% | |
| (3) IFCC method | | 3,52 | 0,30 | 8,6 | 80 | 0 | | | | | | | | | CRV | 3,621 | 0,088 | 24% | 2,75 | 4,49 | 80 | | |
| (3) IFCC method; (60) Roche | | 2,93 | 0,14 | 4,6 | 36 | 0 | CVPG | 2,93 | 0,055 | 18% | 2,4 | 3,46 | | | | | | | 36 | | | | |
| Sample B | | 6,37 | 0,94 | 15 | 116 | | | | | | | 36 | 35 | 97% | | | | | | 80 | 77 | 96% | |
| (3) IFCC method | | 6,80 | 0,78 | 11 | 80 | 0 | | | | | | | | | CRV | 6,886 | 0,16 | 24% | 5,23 | 8,54 | 80 | | |
| (3) IFCC method; (60) Roche | | 5,49 | 0,23 | 4,1 | 36 | 0 | CVPG | 5,49 | 0,092 | 18% | 4,5 | 6,48 | | | | | | | 36 | | | | |
| (22) alpha-amylase | | | | | 114 | | | | | | | 9 | 9 | 100% | | | | | | 105 | 103 | 98% | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 5,17 | 0,28 | 5,4 | 114 | | | | | | | 9 | 9 | 100% | | | | | | 105 | 103 | 98% | |
| (1) IFCC method | | 5,13 | 0,25 | 4,8 | 105 | 0 | | | | | | | | | CRV | 5,246 | 0,14 | 15% | 4,45 | 6,04 | 105 | | |
| (1) IFCC method; (149) Siemens (Dade) | | 6,31 | 0,21 | 3,3 | 9 | 0 | CVPG | 6,31 | 0,26 | 9,5% | 5,71 | 6,91 | | | | | | | 9 | | | | |
| Sample B | | 3,80 | 0,19 | 5,0 | 114 | | | | | | | 9 | 9 | 100% | | | | | | 105 | 103 | 98% | |
| (1) IFCC method | | 3,77 | 0,16 | 4,3 | 105 | 0 | | | | | | | | | CRV | 3,811 | 0,11 | 15% | 3,23 | 4,39 | 105 | | |

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: AKS3/17 - Basic Clinical Chemistry - Serum

Dead line: 28.07.2017

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | | |
|--|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|------|-------|------------------|------------------|------------------|----|-----------------|------------------|-------|-----|------------------|------------------|------------------|------|------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | | |
| (22) alpha-amylase | | | | | 114 | | | | | | | 9 | 9 | 100% | | | | | | | 105 | 103 | 98% | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample B | | 3,80 | 0,19 | 5,0 | 114 | | | | | | | 9 | 9 | 100% | | | | | | | 105 | 103 | 98% | |
| (1) IFCC method; (149) Siemens (Dade) | | 4,41 | 0,17 | 3,9 | 9 | 0 | CVPG | 4,41 | 0,21 | 9,5% | 3,99 | 4,83 | | | 9 | | | | | | | | | |
| (23) AST | | | | | 117 | | | | | | | | | | 0 | | | | | | 117 | 113 | 97% | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,75 | 0,08 | 4,7 | 117 | | | | | | | | | | 0 | CRV | 1,804 | 0,040 | 15% | 1,53 | 2,08 | 117 | 114 | 97% |
| (1) IFCC method | | 1,75 | 0,08 | 4,7 | 117 | 0 | | | | | | | | | | | | | | | 117 | | | |
| Sample B | | 2,51 | 0,13 | 5,1 | 117 | | | | | | | | | | 0 | CRV | 2,474 | 0,060 | 15% | 2,1 | 2,85 | 117 | 113 | 97% |
| (1) IFCC method | | 2,51 | 0,13 | 5,1 | 117 | 0 | | | | | | | | | | | | | | | 117 | | | |
| (24) ALT | | | | | 118 | | | | | | | | | | 0 | | | | | | 118 | 111 | 94% | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 3,99 | 0,17 | 4,2 | 118 | | | | | | | | | | 0 | CRV | 4,094 | 0,090 | 15% | 3,47 | 4,71 | 118 | 113 | 96% |
| (1) IFCC method | | 3,99 | 0,17 | 4,2 | 118 | 0 | | | | | | | | | | | | | | | 118 | | | |
| Sample B | | 2,37 | 0,14 | 5,9 | 118 | | | | | | | | | | 0 | CRV | 2,355 | 0,052 | 15% | 2 | 2,71 | 118 | 113 | 96% |
| (1) IFCC method | | 2,37 | 0,14 | 5,9 | 118 | 0 | | | | | | | | | | | | | | | 118 | | | |
| (26) CK | | | | | 103 | | | | | | | | | | 0 | | | | | | 103 | 102 | 99% | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 6,60 | 0,40 | 6,0 | 103 | | | | | | | | | | 0 | CRV | 7,155 | 0,18 | 20% | 5,72 | 8,59 | 103 | 102 | 99% |
| (1) IFCC method | | 6,60 | 0,40 | 6,0 | 103 | 0 | | | | | | | | | | | | | | | 103 | | | |
| Sample B | | 8,37 | 0,52 | 6,2 | 103 | | | | | | | | | | 0 | CRV | 8,705 | 0,21 | 20% | 6,96 | 10,5 | 103 | 103 | 100% |
| (1) IFCC method | | 8,37 | 0,52 | 6,2 | 103 | 0 | | | | | | | | | | | | | | | 103 | | | |
| (27) gamma-GT | | | | | 116 | | | | | | | | | | 0 | | | | | | 116 | 116 | 100% | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 2,85 | 0,11 | 3,9 | 116 | | | | | | | | | | 0 | CRV | 2,877 | 0,072 | 15% | 2,44 | 3,31 | 116 | 116 | 100% |
| (1) IFCC method | | 2,85 | 0,11 | 3,9 | 114 | 0 | | | | | | | | | | | | | | | 114 | | | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | 2 | | | |
| Sample B | | 3,16 | 0,12 | 3,7 | 116 | | | | | | | | | | 0 | CRV | 3,181 | 0,078 | 15% | 2,7 | 3,66 | 116 | 116 | 100% |
| (1) IFCC method | | 3,16 | 0,12 | 3,7 | 114 | 0 | | | | | | | | | | | | | | | 114 | | | |
| Other | | | | | 2 | 0 | | | | | | | | | | | | | | | 2 | | | |
| (28) LD | | | | | 95 | | | | | | | | | | 0 | | | | | | 95 | 93 | 98% | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 3,71 | 0,14 | 3,9 | 95 | | | | | | | | | | 0 | CRV | 3,829 | 0,085 | 18% | 3,13 | 4,52 | 95 | 93 | 98% |
| (3) IFCC method | | 3,71 | 0,14 | 3,9 | 95 | 0 | | | | | | | | | | | | | | | 95 | | | |
| Sample B | | 5,14 | 0,23 | 4,4 | 95 | | | | | | | | | | 0 | CRV | 5,039 | 0,11 | 18% | 4,13 | 5,95 | 95 | 94 | 99% |
| (3) IFCC method | | 5,14 | 0,23 | 4,4 | 95 | 0 | | | | | | | | | | | | | | | 95 | | | |
| (29) Lipase | | | | | 70 | | | | | | | 57 | 57 | 100% | | | | | | | 0 | | | |
| Samples and groups | [µkat/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,29 | 0,18 | 14 | 70 | | | | | | | 57 | 57 | 100% | | | | | | | 0 | | | |
| (1) Photometry; (1) Abbott | | 1,38 | 0,02 | 1,6 | 7 | 0 | CVPG | 1,38 | 0,022 | 24% | 1,04 | 1,72 | | | 7 | | | | | | | | | |
| (1) Photometry; (12) Beckman Coulter | | 1,19 | 0,14 | 12 | 5 | 0 | CVPG | 1,19 | 0,40 | 24% | 0,904 | 1,48 | | | 5 | | | | | | | | | |
| (1) Photometry; (58) Beckman Coulter (Olympus) | | 1,37 | 0,09 | 6,6 | 18 | 0 | CVPG | 1,37 | 0,052 | 24% | 1,04 | 1,7 | | | 18 | | | | | | | | | |

